Published in Healthcare Mergers, Acquisitions and Ventures Week, March 27th, 2004
The total market for Able's newly approved drug (used in treatment for attention deficit disorder with hyperactivity and exogenous obesity) is estimated to be approximately $4 million according to recent market data.
Able is the first company to receive an ANDA approval for this product and will be the first company...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.